Paediatric brain tumour research: In a recent report US Phrma identified 53 medicines in clinical trial development or FDA review for paediatric cancer of which 12 were specifically associated with brain tumours, while several others were being investigated for solid tumours in general.

The name, indication  and status of the brain tumour medicines or therapies are:  ARC-100 (medulloblastoma) Phase I/II; cintredekin besodotox  (glioma) Phase I; GliAtak (malignant brain tumors), Phase I; Nexavar (glioma), Phase II; nimotuzumab (recurrent glioma), Phase II; PTC299 (CNS cancer) Phase 1; SL-701 (glioma) Phase I/II; Tarceva (recurrent/refractory ependymoma) Phase II; TheraCIM (recurrent DIPG) Phase II; vismodegib (medulloblastoma) Phase II;  Xeloda (gliomas) Phase I; Xerecept (brain edema associated with brain tumors) Phase I/II.

Visas Tarptautinės sergančiųjų galvos smegenų augliais asociacijos 2012 m. sausio mėn. naujienas anglų kalba rasite čia.

Šaltinis: www.theibta.org